메디채널

주메뉴 바로가기
본문 바로가기

기상청 제공

닫기

전체기사

Kelun-Biotech Receives Investigational New Drug Approval for ITGB6-Targeted ADC SKB105 from the NMPA

CHENGDU, China, Jan. 5, 2026 -- Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. ("Kelun-Biotech" or the "Company", 6990.HK) announced that its Investigational New Drug (IND) application for SKB105 (also known as CR-003), an internally developed integrin beta-6 (ITGB6)-targeted antibody-drug conjugate (ADC), has been approved by the Center for Drug Evaluation (CDE) of the National Medical Products Administration (NMPA) of China for the treatment of advanced solid tumors. In December 2025, Kelun-Biotech and Crescent Biopharma, Inc. ("Cresc
- 김갑성 기자
- 2026-01-05 20:00
CTA, 관세•경제 역풍에도 2026년 미국 소비자 기술 시장 5650억 달러로 성장 전망

라스베이거스, 2026년 1월 5일 -- 관세 압박과 경제적 불확실성이 기업 업황에 부담을 주고 있는 가운데 2026년 소비자 기술 산업 매출이 전년 대비 3.7% 성장한 5650억 달러에 달할 것으로 전망됐다. 미국 소비자 기술협회(Consumer Technology Association)®는 4일 CES® 2026 미디어 데이 기간 중 열린 주목할 기술 트렌드(Tech Trends to Watch) 행사에서 이 같은 내용이 담긴 미국 소비자 기술 산업 전망(U.S. Consumer Technology Industry Forecast)을 발표했다. 이날 행사에는 업계 리더들이 모여 최신 기술 혁신을 논의하고, 2026년의 산업 흐름을 전망했다. 이번 CTA 전망은 경제적 불확실성과 공급망 재편, 소비 지출 압박이 겹친 상황에서도 소비자 기술 산업이 회복력을 유지하고 있음을 확인해준다. 게리 샤피로(Gary Shapiro) CTA 회장 겸 최고경영자(CEO)는 "관세와 광범위한 경제적 압박이 심화하는 상황에서도 미국인들은 생산성, 연결성, 삶의 질을 향상시키는 기술에 대한 투자를 놓지 않고 있
- 황정호 기자
- 2026-01-05 19:38
Sisram Medical Reports Completion of NIFDC Testing for DAXXIFY in China

[ 메디채널 김갑성 기자 ] Marking a Key Milestone Toward Market Launch and Strengthening Sisram's Premium Aesthetics Portfolio HONG KONG, Jan. 5, 2026 -- Sisram Medical Ltd (the "Company" or "Sisram", 1696.HK; together with its subsidiaries collectively referred to as the "Group"), a global wellness group offering Energy-Based Devices (EBD), injectables, diagonostics, and other complementary solutions, today announced that its long-acting botulinum toxin type A product, DAXXIFY (trademark in Chinese Mainland达希斐®), has passed the quality testing from National I
- 김갑성 기자
- 2026-01-05 17:36
Kelun-Biotech Announces Breakthrough Therapy Designation Granted in China for Sacituzumab Tirumotecan (sac-TMT) in Combination with Immunotherapy Pembrolizumab for First-Line Treatment of PD-L1-Positive NSCLC

CHENGDU, China, Jan. 5, 2026 -- Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. ("Kelun-Biotech" or the "Company," 6990.HK) today announced that its TROP2-directed antibody-drug conjugate (ADC) sacituzumab tirumotecan (sac-TMT, also known as SKB264/MK-2870) (佳泰莱®) in combination with MSD's anti-PD-1 monoclonal antibody pembrolizumab (KEYTRUDA®[1]) was granted Breakthrough Therapy Designation (BTD) by the Center for Drug Evaluation (CDE) of the National Medical Products Administration (NMPA) of China for the first-line treatment of patients with locally ad
- 김갑성 기자
- 2026-01-05 17:29
JustMarkets Announces Boost Contest for All Clients

HO CHI MINH CITY, Vietnam, Jan. 5, 2026 -- JustMarkets, a worldwide broker with more than 12 years of experience in the online trading realm, is launching the Boost Contest, which represents a large-scale trading activity with the purpose of motivating traders, with the most proficient traders being awarded for their exceptional performance through a number of valuable prizes. This activity will last until the 31st of January, 2026. A Competition Developed with the Goal of Providing More Opportunities for Traders Worldwide Boost Contest competition participants will be t
- 황정호 기자
- 2026-01-05 17:14
Top Broker Ranking List Released: WikiFX Highlights KCM Trade's Growing Influence Across Asia

HONG KONG, Jan. 5, 2026 -- Recently, WikiFX released its latest global forex broker rankings, offering users worldwide an updated perspective on the industry. The list highlights each broker's influence, overall competitiveness, and recent developments, helping traders make more informed decisions in a rapidly evolving market. In China, the top 10 list features established international names such as FXCM, FOREX.com, AvaTrade, XM, IC Markets, GTCFX, Vantage, Startrader, TMGM and KCM Trade. Meanwhile, in Thailand and Vietnam, prominent brokers including AvaTrade, FXCM, StarTrader, XM, E
- 황정호 기자
- 2026-01-05 16:30
Thailand Rings in the New Year at Bangkok's 'Times Square of Asia', Central World

BANGKOK, Jan. 5, 2026 -- Fireworks arced across Bangkok's skyline. Drones lit up the night sky. A sea of people filled the Ratchaprasong district as the city counted down together. At midnight, centralwOrld Bangkok Countdown 2026: The Original – A Tribute to Love transformed the heart of Thailand's capital into a global stage, reinforcing centralwOrld's reputation as the "Times Square of Asia." More than 350,000 people, including international visitors, gathered at the city's most recognisable crossroads to welcome the New Year, turning one of
- 김장윤(JASON KIM) 기자
- 2026-01-05 16:13
Manulife Hong Kong Launches Genesis Centurion Insurance Plan and Prestige Achiever Insurance Plan

[ 메디채널 황정호 기자 ] Two new participating life insurance savings plans designed to empower financial well-being and meet evolving customer needs for flexibility and growth HONG KONG, Jan. 5, 2026 -- Manulife Hong Kong today announced the launch of two new participating life insurance savings plans — Genesis Centurion Insurance Plan and Prestige Achiever Insurance Plan — designed to help customers achieve financial goals with enhanced flexibility and growth potential. Genesis Centurion Insurance Plan is designed to support long-term wealth accumulation and planning, complementing t
- 황정호 기자
- 2026-01-05 13:42
Samsung Unveils World's First 130-Inch Micro RGB TV Featuring Next-Generation Color and Bold New Design

Debuting with advanced picture performance, the new 130-inch Micro RGB TV sets a new standard for ultra-premium displays LAS VEGAS, Jan. 5, 2026 -- Samsung Electronics Co., Ltd. today unveiled the world's first 130-inch Micro RGB TV (R95H model) at CES 2026, marking the debut of its largest Micro RGB display and a bold new design direction for ultra-premium displays. "Micro RGB represents the peak of our picture quality innovation, and the new 130-inch model takes that vision even further," said Hun Lee, Executive Vice President of the Visual Display (V
- 김장윤(JASON KIM) 기자
- 2026-01-05 12:44
GenEditBio Receives FDA Clearance of IND Application for Its Lead In Vivo Genome-Editing Program GEB-101 for TGFBI Corneal Dystrophy

HONG KONG, Jan. 5, 2026 -- GenEditBio Limited ("GenEditBio"), a clinical-stage biotechnology startup focusing on genome-editing therapeutic solutions, today announced that the U.S. Food and Drug Administration (FDA) has cleared the company's Investigational New Drug (IND) application to initiate Phase 1/2 CLARITY trial activities for its lead in vivo genome-editing program GEB-101 for TGFBI corneal dystrophy. The Phase 1/2 CLARITY trial will collect initial data on the safety, tolerability and efficacy of GEB-101 in corneal dystrophy patients with TGFBI
- 김갑성 기자
- 2026-01-05 12:07

이전

21 22 23 24 25 26 27 28 29 30

많이 본 기사

최근기사

2026-01-15_THU

발행인 : 최희정 | 편집인 : 김갑성 |
등록번호: 서울특별시 아53302 | 등록일 2020-09-25 | 전화번호 02-565-7119 |
주소 : 서울특별시 강남구 영동대로 602, 6층 E115 (삼성동)
Copyright @메디채널 Corp. All rights reserved.

UPDATE: 2026년 01월 15일 18시 20분